Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD

Blood

Volumn 113, Issue 3, 2009, Pages 649-658

  Mhyre, Andrew J ^a   Marcondes, A Mario ^a,b   Spaulding, Emily Y ^a   Deeg, H Joachim ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CASPASE 3; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; MICRORNA; PYCARD PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CYTOSKELETON PROTEIN; PYCARD PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; BONE MARROW; CD34 SELECTION; COCULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA; UPREGULATION; BIOSYNTHESIS; CELL COMMUNICATION; CELL LINE; CYTOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL COMMUNICATION; CELL LINE; COCULTURE TECHNIQUES; CYTOSKELETAL PROTEINS; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; HUMANS; MYELODYSPLASTIC SYNDROMES; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STROMAL CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60249093589     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-152686     Document Type: Article

References (43)

1. Li X, Bryant E, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol. 2004;80:140-145.
2. Kerbauy DMB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007;35: 1739-1746.
3. Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996;88:2640-2647.
4. Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63:265-278.
5. Kroger N, Schetelig J, Zabelina T, et al. A fludarabine- based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2001;28:643-647.
6. de Lima M, Shahjahan M, Alamo J, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with AML and MDS [abstract]. Blood. 2004;104 (Part 1):632a.
7. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246-4254.
8. Beg AA, Sha WC, Bronson RT, Baltimore D. Constitutive NF-kB activation, enhanced granulopoiesis, and neonatal lethality in IkBa-deficient mice. Genes Dev. 1995;9:2736-2746.
9. Rupec RA, Jundt F, Rebholz B, et al. Stroma-mediated dysregulation of myelopoiesis in mice lacking IkBa. Immunity. 2005;22:479-491.
10. Kerbauy DMB, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106:3917-3925.
11. Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res. 2003;27:583-591.
12. Hasegawa M, Kawase K, Inohara N, et al. Mechanism of ASC-mediated apoptosis: bid-dependent apoptosis in type II cells. Oncogene. 2007;26:1748-1756.
13. Parsons MJ, Vertino PM. Dual role of TMS1/ASC in death receptor signaling. Oncogene. 2006;25: 6948-6958.
14. Stehlik C, Lee SH, Dorfleutner A, Stassinopoulos A, Sagara J, Reed JC. Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol. 2003;171:6154-6163.
15. Ozoren N, Masumoto J, Franchi L, et al. Distinct roles of TLR2 and the adaptor ASC in IL-1beta/ IL-18 secretion in response to Listeria monocytogenes. J Immunol. 2006;176:4337-4342.
16. Taxman DJ, Zhang J, Champagne C, et al. Cutting edge: ASC mediates the induction of multiple cytokines by Porphyromonas gingivalis via caspase-1-dependent and -independent pathways. J Immunol. 2006;177:4252-4256.
17. Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85:997-1005.
18. Graf L, Iwata M, Torok-Storb B. Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a [letter]. Blood. 2002;100:1509-1511.
19. Kerbauy DMB, Scott B, Abbasi N, Deeg HJ. Arsenic trioxide (ATO) induced apoptosis in myelodysplastic syndrome (MDS): the role of TNFa and NFkB [abstract]. Blood. 2004;104 (Part 1):650a. Abstract 2366.
20. Colter M, Jones M, Heimfeld S. CD34- progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. J Hematother. 1996; 5:179-184.
21. Graf L, Heimfeld S, Torok-Storb B. Comparison of gene expression in CD34- cells from bone marrow and G-CSF mobilized peripheral blood by high-density oligonucleotide array analysis. Biol Blood Marrow Transplant. 2001;7:486-494.
22. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim S-H, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A. 2008;105:2865-2870.
23. Ying SX, Seal S, Abbassi N, et al. Differential effects of bexatrone on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk Lymphoma. 2007;48: 1003-1014.
24. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol. 2008;140:444-453.
25. Platzbecker U, Ward JL, Deeg HJ. Chelerythrin activates caspase-8, down-regulates FLIP long and short, and overcomes resistance to tumour necrosis factor-related apoptosis-inducing ligand in KG1a cells. Br J Haematol. 2003;122:489-497.
26. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of antiapoptotic proteins. Leukemia. 2002;16:1713-1724.
27. Bendall LJ, Makrynikola V, Hutchinson A, Bianchi AC, Bradstock KF, Gottlieb DJ. Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukemia. 1998;12: 1375-1382.
28. Bendall LJ, Kortlepel K, Gottlieb DJ. Bone marrow fibroblast exposure to the inflammatory cytokines tumor necrosis factor-alpha and interferongamma increases adhesion of acute myeloid leukemia cells and alters the adhesive mechanism. Exp Hematol. 1997;25:132-139.
29. Lagneaux L, Delforge A, De Bruyn C, Bernier M, Bron D. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma. 1999;35:445-453.
30. Awaya N, Rupert K, Bryant E, Torok-Storb B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol. 2002; 30:937-942.
31. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma. 2000;37:405-414.
32. Sekeres MA, List A. Immunomodulation in myelodysplastic syndromes. Best Pract Res Clin Haematol. 2006;19:757-767.
33. Secchiero P, Zauli G. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol. 2008; 15:42-48.
34. Isufi I, Seetharam M, Zhou L, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27:543-552.
35. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factorrelated apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98:3058-3065.
36. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A. 2006; 103:3316-3321.
37. Shioya M, Nishida A, Yagi Y, et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol. 2007;149:480-486.
38. Netea MG, Lewis EC, Azam T, et al. Interleukin- 32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci U S A. 2008;105:3515-3520.
39. Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W. Expression of FLIPlong and FLIPshort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia. 2003;17:2460-2466.
40. Lukashev M, LePage D, Wilson C, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res. 2006;66:9617-9624.
41. Kaufmann Y, Amariglio N, Rosenthal E, Hirsch YJ, Many A, Rechavi G. Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma. J Immunol. 2005;175:6940-6947.
42. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006;66:2328-2337.
43. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110: 4396-4405.